Don't Judge Polydeoxyribonucleotide by Its Cover
Journal
Pain medicine (Malden, Mass.)
Journal Volume
23
Journal Issue
7
Pages
1348
Date Issued
2022-07-01
Author(s)
Abstract
Dear Editor, Polydeoxyribonucleotide (PDRN) was recently introduced as an injection material to reduce pain. It has been reported to exert anti-inflammatory effects by lowering the expression of inflammatory cytokines [1, 2]. Several clinical studies have reported the successful treatment of musculoskeletal pain of varying etiologies with PDRN injections [2, 3]. These positive reports have encouraged clinicians to use PDRNs to manage musculoskeletal pain. Furthermore, PDRN is reported to be a nucleoside that regenerates and repairs cellular damage by interacting with the A2 purinergic receptor and accelerating fibroblast differentiation [2]. To determine whether PDRN can be used in clinical practice, we reviewed previous studies on the effect of PDRN on pain control in musculoskeletal disorders and assessed the quality of these studies. In total, 18 previous studies on the effect of PDRN in controlling musculoskeletal pain have been published (Table 1). PDRN has been used to treat various disorders, including rotator cuff pathology, lateral epicondylitis, posterior tibial tendon dysfunction, anterior cruciate ligament injury, plantar fasciitis, radicular pain, sciatic neuropathy, carpal tunnel syndrome, complex regional pain syndrome type II, ischiofemoral impingement syndrome, pes anserine bursitis, hemiplegic shoulder, and knee osteoarthritis. All 18 studies reported positive pain-reducing effects for PDRN; however, none has reported its negative effects. However, some important issues must be considered when determining the clinical administration of PDRN for controlling musculoskeletal pain.
SDGs
Publisher
OXFORD UNIV PRESS
Type
letter